<DOC>
	<DOCNO>NCT01878318</DOCNO>
	<brief_summary>This open-label , single arm study evaluate effect RoActemra/Actemra combination methotrexate articular damage hand ( synovitis/osteitis erosion ) patient moderate severe rheumatoid arthritis inadequate response non-biological disease-modifying ante-rheumatic drug ( DMARDs ) . Patients receive RoActemra/Actemra 8 mg/kg intravenously every 4 week 24 week .</brief_summary>
	<brief_title>A Study The Effect RoActemra/Actemra ( Tocilizumab ) Combination With Methotrexate Articular Damage The Hand Patients With Moderate Severe Rheumatoid Arthritis Who Have Inadequate Response Non-Biological DMARDs</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Diagnosis rheumatoid arthritis accord ACR/EULAR classification ( 2010 ) &gt; /= 6 month duration Active moderate severe rheumatoid arthritis ( DAS &gt; /= 3.2 ) Swollen joint count ( SJC ) &gt; /= 6 , tender joint count &gt; /= 8 Synovitis dominant hand Inadequate response stable dose nonbiological DMARD least 3 month Oral corticosteroid must stable dose least 25 28 day first dose study drug Patient outpatient treatment Major surgery ( include joint surgery ) 8 week prior screen , plan major surgery within 6 month randomization Rheumatic autoimmune disease rheumatoid arthritis American College Rheumatology ( ACR ) functional class IV History current inflammatory joint disease rheumatoid arthritis Previous inadequate response biologic DMARD ; prior biologic therapy longer 1 month allow discontinue reason tolerability least 6 month prior study recruitment Intraarticular parenteral corticosteroid within 6 week prior study start Inadequate hematologic , renal liver function Positive hepatitis B , hepatitis C HIV infection Pregnant lactate woman History severe allergic reaction anaphylaxis human , humanized mural monoclonal antibody Current infection history recurrent infection History currently active primary acquire immunodeficiency Active tuberculosis require treatment previous 3 year Body weight &gt; 150 kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>